Currently, there are 66.77M common shares owned by the public and among those 62.96M shares have been available to trade.
Insiders at the company have transacted a total of 9 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 1,482,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 2.7422, down -0.92%. The company’s stock has a 5-day price change of -2.00% and 69.50% over the past three months. AQST shares are trading 33.42% year to date (YTD), with the 12-month market performance up to 264.19% higher. It has a 12-month low price of $0.72 and touched a high of $2.95 over the same period. AQST has an average intraday trading volume of 638.98K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.64%, 14.86%, and 39.03% respectively.
Institutional ownership of Aquestive Therapeutics Inc (NASDAQ: AQST) shares accounts for 35.74% of the company’s 66.77M shares outstanding.
It has a market capitalization of $179.95M and a beta (3y monthly) value of 2.75. The earnings-per-share (ttm) stands at -$0.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.33% over the week and 5.64% over the month.
Analysts forecast that Aquestive Therapeutics Inc (AQST) will achieve an EPS of -$0.08 for the current quarter, -$0.06 for the next quarter and -$0.25 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.11 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.23 a year ago. Earnings per share for the fiscal year are expected to increase by 88.84%, and -138.67% over the next financial year.
Looking at the support for the AQST, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on April 07, 2021, with the firm’s price target at $7.
